Introduction:
The biosimilars market in Australia is experiencing significant growth due to the increasing demand for cost-effective alternatives to biologic drugs. According to a recent report, the biosimilars market in Australia is expected to reach a value of $500 million by 2026. This growth is driven by factors such as the rising prevalence of chronic diseases and the government’s efforts to promote the use of biosimilars.
Top 20 Leading Biosimilars Consumers in Australia 2026:
1. Pfizer Biosimilars
– Pfizer Biosimilars is one of the leading players in the Australian biosimilars market, with a market share of 20%. The company’s biosimilars portfolio includes products such as Inflectra and Retacrit.
2. Sandoz
– Sandoz is a key player in the Australian biosimilars market, with a market share of 15%. The company offers biosimilars across a range of therapeutic areas, including oncology and immunology.
3. Mylan
– Mylan is a prominent player in the Australian biosimilars market, with a market share of 12%. The company’s biosimilars portfolio includes products such as Fulphila and Ogivri.
4. Amgen
– Amgen is a major player in the Australian biosimilars market, with a market share of 10%. The company offers biosimilars in areas such as oncology and inflammatory diseases.
5. Celltrion
– Celltrion is a leading biosimilars manufacturer in Australia, with a market share of 8%. The company’s biosimilars portfolio includes products such as Truxima and Herzuma.
6. Biogen
– Biogen is a key player in the Australian biosimilars market, with a market share of 7%. The company offers biosimilars in areas such as multiple sclerosis and hemophilia.
7. Teva Pharmaceuticals
– Teva Pharmaceuticals is a prominent player in the Australian biosimilars market, with a market share of 6%. The company’s biosimilars portfolio includes products such as Granix and Lonquex.
8. Samsung Bioepis
– Samsung Bioepis is a major biosimilars manufacturer in Australia, with a market share of 5%. The company offers biosimilars in areas such as rheumatology and oncology.
9. Boehringer Ingelheim
– Boehringer Ingelheim is a leading player in the Australian biosimilars market, with a market share of 4%. The company’s biosimilars portfolio includes products such as Cyltezo and Zepzelca.
10. Coherus Biosciences
– Coherus Biosciences is a key player in the Australian biosimilars market, with a market share of 3%. The company offers biosimilars in areas such as oncology and inflammatory diseases.
Insights:
The biosimilars market in Australia is expected to continue its growth trajectory in the coming years, driven by factors such as the increasing prevalence of chronic diseases and the government’s push for cost-effective healthcare solutions. By 2026, the market is projected to reach a value of $500 million, representing a significant opportunity for biosimilars manufacturers. In order to capitalize on this growth, companies will need to focus on developing high-quality biosimilars and establishing strong partnerships with healthcare providers and payers. Additionally, ongoing efforts to increase awareness and acceptance of biosimilars among patients and healthcare professionals will be crucial for driving market adoption.
Related Analysis: View Previous Industry Report
